Sitemap

74 Years of Galenika: Investments And Business Success In The First Half Of 2019

OTP Banka Srbija Enables Contactless Payment Via Google Pay

In cooperation with Google and Mastercard, OTP...

Real Estate Market In Serbia Worth Two Billion Euros

This year, real estate turnover increased by...

Leaders Of 44 Countries Invited To The First Meeting Of The European Political Community

Representatives of 44 countries have been invited to the first meeting of the European political community, which will be...

Serbian Flag In Times Square

The flag of Serbia with a message about friendship between Serbia and the United States, as well as an...

Vučić At The UN: What Is The Difference Between The Territorial Integrity Of Ukraine And Serbia?

What is the difference between the territorial integrity of Ukraine and the territorial integrity of Serbia, which was violated...

Scientists In China Create World’s First Cloned Wild Arctic Wolf

The successful cloning of the species which is native to the High Arctic tundra of Canada's Queen Elizabeth Islands,...

Korea Sees Serbia As One Of The Most Important Investment Destinations

The Republic of Korea recognizes Serbia as one of the most important investment destinations in Europe and is ready...

Demonstrating the vision and readiness to adapt to the latest business trends and market demands, the domestic pharmaceutical company Galenika a.d., which became part of the international NC Group, one of the largest pharmaceutical company in Latin America, in the first half of 2019 reached the gross sales of its products in the Serbian market of 27.4 million euros, an increase of 13% compared to the same period in 2018 and thus has made a significant shift from fourth to the second place according to the market share in Serbia*.

In the first half of 2019, Galenika also increased the production of its product range by as much as 43.7% compared to the same period in 2018. This year, the company has so far obtained licenses for placing 6 products on the market, which has expanded the portfolio of Galenika in the product-groups used in the treatment of cardiovascular diseases and hypertension, diabetes, antidepressant and dermatics.

The plan for the current year is the granting of a licensing for a total of 10 products, where among the new products there will also be those who represent novelty in therapy, both in the application of a different pharmaceutical form in comparison with previous practice, as well as for greater safety in relation to other products from the same pharmacological group on the market.

“In order to create a modern and competitive company, and with our strong commitment to investing in development, the company raises internal capacities through educational programs and the most up-to-date employee training. Additionally, in the year when Galenika is proudly celebrating the 74th business jubilee, we have invested in state-of-the-art software for advanced management of all business processes – SAP S4HANA Cloud, which made our company one of the pioneers of digital transformation in Central and Eastern Europe. Current investments are just beginning on our decisive road ahead, determined to Galenika’s again become the leader in the region,” said Ricardo Vian Marques, Executive Director for Operational Affairs of Galenika.

As Marques noted, in the next three years Galenika expects a trend of doubling sales in the Serbian market.

As a company committed to improving the health and quality of life of its patients and beneficiaries of products, with the aim of further development of therapy in the areas of cardiovascular diseases, central nervous system diseases and antibiotics, Galenika launched the work of its Scientific Committees, whose members are some of the most eminent medical experts in Serbia.

In accordance with its mission, through implementing the latest knowledge in the field of pharmaceutical technology, Galenika continued its development activities within its Institute for Research and Development, and after 8 years, a new product was launched – Flonivin plus.

Related Articles

Milorad Ilić, Galenika

Pharmaceutical Operations In The EU

Over the course of the previous three years, Galenika has undergone an intensive period of investment and transformation, thanks to which it has repositioned...

Ljiljana Topić, Director, Galenika Pharmacia

Nurturing It’s Own Leadership Position

Galenika Pharmacia produces more than 50 different medical devices - sterile and non-sterile compresses, plaster strips, bandaid plasters, bandages and sanitary materials, vehicle first...

Ricardo Vian Marques, General Manager, Galenika a.d. Beograd

Future-Orientated Company

Over the course of 2020, Galenika continued its trend from the previous year by growing faster than the market, more than 50% faster. It...

Ljiljana Topić, Director, Galenika Pharmacia

We’re Here When Times Are Hardest

Galenika Pharmacia is a factory that produces complete sanitary consumables – from compresses, gauzes and bandages, via disinfectants, to surgical masks that have become...

75 Years Of Galenika

In the jubilee year, Galenika a.d. Belgrade records constant growth in all segments of its business. In the first half of 2020, Galenika achieved...

Galenika: What is most valuable to all of us?

At the time of the pandemic, the company Galenika a.d. is, more intensively than ever, dedicated to its most important task - preserving human...

Galenika donates Hydroxychloroquine Sulfate worth 400,000 Euro in fight against COVID-19

Galenika a.d. Belgrade produced and placed 372,000 tablets of the medicine Hydroxychloroquine Sulfate on the disposal of the Government of Serbia The value of the...

Ljiljana Topić, Director of Galenika Pharmacia

Expanding Production And Markets

Galenika Pharmacia emerged through separation from company Galenika Holding seven years ago, with the aim of contributing to the improvement of quality of life...